세계의 대장암 진단 시장은 2024년에 152억 달러로 평가되었고 2025년부터 2034년에 걸쳐 CAGR 8.9%를 나타낼 것으로 예측됩니다.
대장암(CRC)은 세계에서 가장 많이 진단되는 암 중 하나이며, 매년 수백만 명이 이환하고 있습니다.
대장암 진단 시장은 이미징 기술, 리퀴드 바이옵시, AI 탑재 진단 툴의 지속적인 진보에 의해 급속히 확대되고 있습니다. 와 집 스크리닝 모두에 대응하는 고정밀 비침습적인 검사 솔루션의 개발에 적극적으로 투자하고 있습니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 152억 달러 |
| 예측 금액 | 351억 달러 |
| CAGR | 8.9% |
대장암 진단 시장은 혈액검사, 대변검사, 영상검사, 생검, 기타 진단법 등의 검사 유형별로 구분됩니다. 특히 PET-CT 스캔과 AI 지원 방사선 검사와 같은 고급 이미지 기술은 대장 악성 종양의 조기 발견에 중요한 역할을 합니다. DNA 스크리닝을 포함한 대변 기반 검사는 비 침습적 성질로부터 지지를 받고 있으며 대규모 스크리닝 프로그램에 선호되는 옵션입니다.
시장은 더욱 최종 용도에 따라 분류되어 병원, 화상진단센터, 암연구기관이 주요 부문으로 부상하고 있습니다. 의료 전문가, 종합적인 CRC 스크리닝 프로그램을 이용할 수 있기 때문에 병원은 주요 진단 환경으로 자리매김하고 있습니다.
미국의 대장암 진단 시장은 조기 발견 솔루션에 대한 강한 수요를 반영하여 2024년에 50억 달러를 창출하였습니다. 그리고 CRC 스크리닝이 보다 친숙해져 개인이 조기 발견을 향해 적극적으로 행동할 수 있게 되었습니다.
The Global Colorectal Cancer Diagnostics Market was valued at USD 15.2 billion in 2024 and is projected to grow at a CAGR of 8.9% from 2025 to 2034. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide, affecting millions of individuals each year. With CRC incidence rates rising, particularly among younger adults, the need for accurate, efficient, and early diagnostic solutions has never been more critical. Early detection significantly improves survival rates, making advanced diagnostic technologies essential for timely intervention.
The market for colorectal cancer diagnostics is expanding rapidly due to continuous advancements in imaging technologies, liquid biopsy, and AI-powered diagnostic tools. Increasing awareness campaigns and government-backed CRC screening programs across key regions are further driving demand for reliable and accessible diagnostic methods. Leading market players are actively investing in the development of high-precision, non-invasive testing solutions that cater to both clinical settings and at-home screening. The growing adoption of stool-based DNA tests, blood biomarker screenings, and AI-driven imaging solutions is revolutionizing CRC diagnostics, ensuring patients receive early and accurate assessments.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $15.2 Billion |
| Forecast Value | $35.1 Billion |
| CAGR | 8.9% |
The colorectal cancer diagnostics market is segmented by test type, including blood tests, stool tests, imaging tests, biopsies, and other diagnostic methods. Imaging tests dominated the market with a 49.6% share in 2024, driven by the rising demand for early cancer detection and accurate disease assessment. Advanced imaging technologies, particularly PET-CT scans and AI-assisted radiology, play a crucial role in detecting colorectal malignancies at an early stage. These high-precision tools enhance diagnostic accuracy, facilitating personalized treatment approaches. Stool-based tests, including fecal occult blood tests and CRC DNA screenings, are also gaining traction due to their non-invasive nature, making them a preferred choice for large-scale screening programs.
The market is further categorized based on end use, with hospitals, diagnostic imaging centers, and cancer research institutions emerging as key segments. Hospitals accounted for 40.8% of the market share in 2024, primarily due to their advanced oncology and gastroenterology departments. The availability of comprehensive diagnostic facilities, skilled healthcare professionals, and integrated CRC screening programs has positioned hospitals as the leading diagnostic setting. Governments worldwide continue to implement nationwide colorectal cancer screening initiatives, further fueling hospital-based diagnostic testing.
The U.S. colorectal cancer diagnostics market generated USD 5 billion in 2024, reflecting a strong demand for early detection solutions. The rising incidence of CRC among younger populations, combined with growing awareness of the importance of early screening, is driving market expansion. The increased availability of at-home diagnostic solutions, such as blood biomarkers and stool-based tests, has made CRC screening more accessible, allowing individuals to take proactive steps toward early detection. As technological advancements continue to shape the diagnostic landscape, demand for highly accurate, non-invasive, and AI-powered colorectal cancer screening solutions is expected to surge, solidifying the U.S. as a key growth hub for the global market.